NAD+, NMN and NR: Different Molecules, Different Research Questions

NAD+, NMN and NR often appear together in discussions of cellular metabolism. They are related, but a result for one is not automatically evidence for the others. This guide compares their identities and three selected human studies published in 2018 and 2021. It explains what those experiments measured rather than ranking products or claiming to summarize every current trial.

At a glance:

• NAD+ is a coenzyme; NMN and NR are different precursor molecules. None is a peptide.

• Increasing a laboratory biomarker does not, by itself, demonstrate better health or longer life.

• Findings for studied NR or NMN preparations do not validate a research vial labeled NAD+.

Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells research materials. This commercially interested, AI-assisted summary is not an independent scientific review. Our source-access limits appear below.

1. How are NAD+, NMN and NR related?

NAD+ means nicotinamide adenine dinucleotide. It participates in cellular reactions as a coenzyme and as a substrate used by enzymes. NR, nicotinamide riboside, and NMN, nicotinamide mononucleotide, can contribute to NAD+ synthesis through metabolic pathways. A 2004 experimental report identified NR kinases in yeast and humans and established an NR-dependent route to NAD+. That was a biochemical discovery, not a clinical comparison of commercial products. Bieganowski and Brenner, 2004 — abstract

This distinction matters when a headline says that a study “increased NAD+.” That phrase may describe the result of an assay, while the substance studied was NR or NMN. The original NR pathway report and NMN clinical report illustrate these different uses of the names.

2. What do two NR trials show about different endpoints?

In 2018, Martens and colleagues conducted a randomized, blinded crossover trial in healthy middle-aged and older adults. Twenty-four participants completed both six-week periods. NR increased NAD+ measured in peripheral blood mononuclear cells compared with placebo. The report describes generally good short-term tolerability, but also mild adverse events; it does not establish lifetime safety. ChromaDex supplied study materials and partial funding. Original study, results and acknowledgments

A change in those blood cells does not establish the same change in every organ. Nor is it a measurement of lifespan. The study's exploratory physiological findings should remain distinguishable from its biochemical result.

A different 2018 trial by Dollerup and colleagues randomized 40 sedentary men with obesity to NR or placebo for 12 weeks. The abstract reports no improvement in insulin sensitivity, whole-body glucose metabolism or body composition. These unchanged outcomes belong beside the positive biomarker findings from other studies. Dollerup and colleagues, 2018 — abstract

The two reports are not simply contradictory votes. They examined different participants and questions. A useful comparison records the population, endpoint and duration before deciding whether findings actually disagree.

3. What did the NMN study in women with prediabetes find?

Yoshino and colleagues studied 25 postmenopausal women with prediabetes and overweight or obesity in a ten-week randomized, blinded trial. Thirteen completed the NMN group and 12 the placebo group. The researchers reported improved insulin-stimulated glucose disposal and muscle insulin signaling. Liver and adipose-tissue insulin sensitivity did not improve, and the findings did not establish weight loss. Original study, results and Table 1

The measurement was a controlled metabolic assessment, not a demonstration that every person would experience an everyday benefit. The selected population and short follow-up also limit generalization.

A published comment challenged an imbalance in liver fat between the groups at baseline. The authors replied that muscle insulin sensitivity was similar initially and that the liver-fat difference did not negate their muscle finding. Both parts of that exchange are relevant; this guide does not independently resolve it. Brenner's comment — abstract, Klein and Yoshino's response — abstract

This is a reason to read the research conversation around a study, not just its title. A small positive trial can support a specific follow-up question while leaving broader effectiveness unsettled.

4. Why is a biomarker change not proof of an anti-aging effect?

An endpoint is the outcome a study measures. Blood-cell NAD+, an insulin-sensitivity measurement, body composition, daily function and lifespan are different endpoints. A biological mechanism may motivate a trial, but it cannot replace the trial's actual outcome.

The selected NR and NMN trials above do not establish that humans live longer because of these interventions. They also do not provide a direct comparison establishing that one of NAD+, NMN or NR is universally superior. Comparing separate trials as if participants had been randomized between all three substances would create a comparison the researchers did not perform.

When reading an “anti-aging” claim, ask what would count as success. A specified change in a specified laboratory measurement can be checked against a paper. An undefined promise of rejuvenation cannot. For a related example of separating human observations from animal experiments, see our MOTS-C evidence guide.

5. What should a useful research record contain?

Keep the following fields beside each citation:

• The exact studied molecule and preparation.

• The participants or experimental model, including selection criteria.

• The comparator, duration and predefined outcomes.

• Positive, unchanged and adverse findings, plus funding disclosures.

• The claim the study can support, and the next question it leaves open.

Keep material documentation in a separate record. An NR or NMN study cannot authenticate a NAD+ research vial's identity, amount, purity or suitability. Matching a biological pathway is not the same as matching a tested preparation. Our guide to reading a peptide study explains the same evidence-checking approach, and the COA methods guide covers material records.

Review method and source access

Checked November 8, 2026: the NR pathway and Dollerup abstracts, selected full-text results and disclosures from Martens and Yoshino, and the published comment/response abstracts. These are selected historical examples, not a systematic or exhaustive review of current NAD-related research. Participant-level data, every supplement and all later trials were not reviewed. No new experiment or independent product testing was performed.

Catalog materials are for lawful laboratory research only, not human or veterinary use. This guide provides no dosing or administration instructions and does not recommend substituting research materials for clinical care.